MedTrace Logo

Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma

NCT00169195 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2015-09-02

No results posted yet for this study

Summary

The Purpose of this study is to evaluate the efficacy and the safety of R-GEMOX in refractory/relapsed patients with CD20-positive large B-cell lymphoma who are not eligible for autologous transplantation.

Conditions

  • Diffuse Large Cell Lymphoma

Interventions

DRUG

Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)

Sponsors & Collaborators

Principal Investigators

  • Corinne Haioun, MD · Hôpital Henri Mondor, Créteil, France

  • Corinne Haioun, MD · Hôpital henri Mondor, Créteil, France

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-04-30
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00169195 on ClinicalTrials.gov